Analyst Ratings February 12, 2026

TD Cowen Reinstates Hold on XOMA After Generation Bio Deal; Analysts Weigh Royalty Portfolio Value

Reinstatement follows February acquisition of Generation Bio as analysts assess revenue potential from an expanding royalty stream

By Hana Yamamoto XOMA
TD Cowen Reinstates Hold on XOMA After Generation Bio Deal; Analysts Weigh Royalty Portfolio Value
XOMA

TD Cowen has resumed coverage of XOMA, Ltd. with a Hold rating after the company's acquisition of Generation Bio. The firm highlighted XOMA's sizable royalty portfolio and robust recent revenue growth, while noting it needs more confidence in the revenue prospects and asset valuation before moving to a more positive rating. XOMA's balance sheet strength and recent corporate developments, including a CFO change and a revised collaboration with Takeda, add context to the outlook.

Key Points

  • TD Cowen reinstated coverage on XOMA with a Hold rating after XOMA acquired Generation Bio, which closed on February 9, 2026.
  • XOMA's royalty portfolio exceeds 120 assets; revenue increased 118.02% to $47.11 million over the last twelve months with a 95.13% gross profit margin.
  • Corporate moves include a CFO transition to Jeffrey Trigilio and an amended Takeda collaboration that shifts majority royalty interest back to Takeda while leaving XOMA with a reduced royalty and possible milestones.

TD Cowen has reinstated coverage on XOMA, Ltd. (NASDAQ:XOMA) with a Hold rating following the company's completion of its acquisition of Generation Bio, the research firm said. The stock is quoted at $23.57, and TD Cowen flagged valuation metrics including a price-to-earnings ratio of 28.97 and a price/earnings-to-growth ratio of 0.24.

According to TD Cowen analyst Phil Nadeau, the Generation Bio acquisition closed on February 9, 2026. TD Cowen pointed to XOMA's liquidity as a buffer during integration - InvestingPro data shows a current ratio of 3.91, indicating the company has ample short-term resources to manage the transaction.

The firm emphasized XOMA's progress building a royalty portfolio, describing the company as "prolific" in assembling more than 120 assets. That portfolio has coincided with a rapid top-line expansion: revenue rose 118.02% over the last twelve months to $47.11 million. Margins have been notable as well, with a reported gross profit margin of 95.13%.

On the basis of TD Cowen's analysis of XOMA's financial trajectory, the firm expects the company to reach profitability in 2027. Despite that projected path to profit, TD Cowen retained its Hold rating while it builds conviction in the revenue potential and the intrinsic value of the royalty assets.


Corporate developments and partner agreements

In parallel with the acquisition, XOMA Royalty Corporation announced an executive change: Thomas Burns is stepping down as chief financial officer, and Jeffrey Trigilio will assume the role. Trigilio's background includes prior positions at Obsidian Therapeutics and Cullinan Therapeutics, according to the company statement included in the research note.

XOMA also amended a collaboration agreement with Takeda. Under the revised terms, Takeda regains a majority of the royalty interest in mezagitamab, while XOMA retains a reduced royalty plus potential milestone payments. Following that contractual adjustment, Leerink Partners reiterated an Outperform rating on XOMA with a $45 price target.


Market reactions and partner developments

The Generation Bio acquisition was structured at $4.29 per share plus a contingent value right per share. The deal prompted Jefferies to lower its recommendation on Generation Bio from Buy to Hold and to cut its price target to $5.00.

Separately, a clinical trial conducted by Rezolute Bio, a partner in an unrelated program, failed to meet its primary and secondary endpoints in a study of congenital hyperinsulinism. Despite that trial outcome, Benchmark maintained a Buy rating on XOMA and assigned a $50 price target.


Takeaway

TD Cowen's reinstatement of coverage with a Hold reflects a balance between clear strengths - a deepening royalty asset base, strong recent revenue growth, high gross margins and a solid liquidity position - and remaining uncertainty about how those assets will translate into durable revenue streams and value. The company faces a series of near-term catalysts and changes in partner economics that analysts are parsing as they calibrate conviction on XOMA's path to profitability.

Risks

  • Uncertainty about the revenue potential and fair value of XOMA's expanded royalty portfolio - impacts biotech and healthcare royalty financing.
  • Changes to collaboration economics, such as the Takeda amendment reducing XOMA's royalty interest in mezagitamab, could affect future royalty income - impacts pharmaceutical partnerships and royalty revenue streams.
  • Clinical trial setbacks among partners, exemplified by the Rezolute Bio trial failing to meet endpoints, create downstream risk for partner-led programs that could influence investor sentiment in biotech securities.

More from Analyst Ratings

HSBC Lowers Synopsys Rating to Hold, Flags 2026 as Transition Year Feb 21, 2026 DA Davidson Cuts Uber Price Target Citing Elevated Investment; Buy Rating Intact Feb 20, 2026 Freedom Capital Markets Raises Freeport-McMoRan to Buy, Cites Copper Supply Tightness Feb 20, 2026 BofA Lifts CF Industries Price Target After Strong Q4 EBITDA; Maintains Underperform Rating Feb 20, 2026 Truist Lifts Tandem Diabetes Price Target as Company Shifts Toward Pharmacy Model Feb 20, 2026